Bionano Genomics (BNGO) Cash from Investing Activities (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Cash from Investing Activities data on file, last reported at $5.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 138.8% year-over-year to $5.5 million; the trailing twelve-month figure through Mar 2026 stood at $6.8 million (down 44.4% YoY), and the FY2025 full-year result was -$12.7 million, down 117.26% from the prior year.
• Cash from Investing Activities rose to $5.5 million in Q1 2026, from $4.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $47.6 million in Q1 2024 to a low of -$55.4 million in Q4 2023.
• A 5-year average of $10.2 million and a median of $8.0 million in 2022 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities surged 133283.33% in 2022 and plunged 576.94% in 2023, its largest moves.
• Tracing BNGO's Cash from Investing Activities over 5 years: stood at $11.6 million in 2022, then sank by 576.94% to -$55.4 million in 2023, then surged by 105.41% to $3.0 million in 2024, then soared by 33.77% to $4.0 million in 2025, then surged by 36.12% to $5.5 million in 2026.
• Business Quant data shows BNGO's Cash from Investing Activities at $5.5 million in Q1 2026, $4.0 million in Q4 2025, and -$4.7 million in Q3 2025.